Building on its proprietary Molecularly Targeted Anti-HPV Technology, The SRP Group has continuously advanced the development and commercialization of the REBACIN® product portfolio, progressing from local anti-HPV products to therapeutic drug development for HPV-related cervical disease.
2009 — REBACIN® Antiviral Gel
Approved and launched in China as a mucosal disinfectant, marking the first commercialization of the REBACIN® technology platform.
2018 — REBACIN® Anti-HPV Gel Dressing
Approved in China as a Class II medical device, further advancing the application of REBACIN® technology for local management of HPV infection.
2026+ —REBACIN® Class D Anti-HPV Gel Dressing
A Class D medical device with drug in a secondary role is under development for the management of high-risk HPV infection, including persistent high-risk HPV infection.
Together, these programs demonstrate the continued translation and evolution of the Group’s core anti-HPV technology—from commercialized local products to the development of therapeutic candidates targeting HPV-related cervical disease.